Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for intravenous administration in systemic indications. It has a risk-sharing collaboration agreement with SFJ Pharmaceuticals Group for the development of APL-2 in hematologic indications. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [03/21/2019 08:00 PDT] APLS Expected to Trade Down After Bearish Patterns Develop
• [03/05/2019 07:58 PST] APLS Expected to Trade Up After Bullish Patterns Develop
• [03/01/2019 13:02 PST] Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Up By 100.00% ($14.89) After BUYINS.NET SqueezeTrigger Report Released on Monday, February 25th 2019 at a Price of $14.890.
• [02/25/2019 13:01 PST] APLS SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.